Weight-loss pill helps patients lose 6% of body weight in three months: data
Summary
- Novo Nordisk's daily oral Wegovy pill resulted in an average 6.2% body weight loss over three months based on real-world data.
- Study participants starting the pill between January 5 & February 7, 2026, lost an average of 6.3 kg (13.9 pounds) from a baseline of 103.0 kg (227 pounds).
- The analysis covered 5,872 adults on the Ro telehealth platform who had never used weight-loss drugs before & stayed on the medication for three months.
- Approximately 60% of participants lost at least 5% of their body weight, while roughly one in six lost at least 10%.
- These real-world findings broadly replicated the 5.5% weight loss seen in Novo's late-stage trials at 12 weeks.
- The oral formulation helps Novo Nordisk regain ground lost to Eli Lilly in the obesity-drug market following a 70% stock decline from its peak.
- Oral treatments now represent roughly one-third of U.S. obesity prescriptions, with Novo securing over 80% of new oral prescriptions.
- Real-world data from September showed patients switching from injections to Novo's pill continued to lose weight.
- Separate studies indicated oral Wegovy led to a 14% weight reduction over 64 weeks, compared to Eli Lilly's Foundayo which showed an 11% reduction over 72 weeks.
Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2 per cent of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.